IP Library › Granted Patent US 12,472,146
Granted Patent B2
US 12,472,146 · App. 17/883,902 · Granted Nov 18, 2025

Extended release pharmaceutical formulation

Inventors: Paul William Glue (Dunedin, NZ); Natalie June Medlicott (Dunedin, NZ); Peter William Surman (Auckland, NZ)
Assignee: Douglas Pharmaceuticals, Ltd.
A61K9/2031A61K9/0053A61K9/2013A61K9/2813A61K9/2853A61K9/2866A61K31/135A61K45/06A61P25/22A61P25/24A61K9/2095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,472,146
App. No.
17/883,902
Granted
Nov 18, 2025
Kind
B2
Abstract

The disclosure provides an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

Claims (102)

1 . A solid, oral, extended release pharmaceutical tablet comprising a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof,

wherein said tablet comprises greater than about 25 mg of the active agent and is administered to a patient in a dosage amount of active agent selected from the group consisting of about 30 mg, about 60 mg, about 120 mg, and about 240 mg, and wherein when said tablet is administered to the patient said tablet provides a pharmacokinetic parameter selected from the group consisting of:

after administration of a single dose of 60 mg ketamine a mean ketamine Cmax of about 10 ng/ml or a ketamine Cmax between about 5 and about 15 ng/ml;

after administration of a single dose of 120 mg ketamine a mean ketamine Cmax of about 16 ng/ml or a ketamine Cmax between about 7 and about 32 ng/ml;

after administration of a single dose of 240 mg ketamine a mean ketamine Cmax of about 38 ng/ml or a ketamine Cmax between about 19 and about 47 ng/ml;

after administration of a single dose of 60 mg of the active agent a mean norketamine Cmax of about 74 ng/ml or a norketamine Cmax between about 59 and about 91 ng/ml;

after administration of a single dose of 120 mg of the active agent a mean norketamine Cmax of about 161 ng/ml or a norketamine Cmax between about 90 and about 250 ng/ml;

after administration of a single dose of 240 mg of the active agent a mean norketamine Cmax of about 315 ng/ml or a norketamine Cmax between about 222 and about 394 ng/ml;

after administration of a single dose of 60 mg ketamine a mean ketamine AUC 0-∞ of about 79 ng·h/mL or a ketamine AUC 0-∞ between about 36 and about 135 ng·h/mL;

after administration of a single dose of 120 mg ketamine a mean ketamine AUC 0-∞ of about 197 ng·h/mL or a ketamine AUC 0-∞ between about 93 and about 460 ng·h/mL;

after administration of a single dose of 240 mg ketamine a mean ketamine AUC 0-∞ of about 389 ng·h/mL or a ketamine AUC 0-∞ between about 231 and about 521 ng·h/mL;

after administration of a single dose of 60 mg of the active agent a mean norketamine AUC 0-∞ of about 872 ng·h/mL or a norketamine AUC 0-∞ between about 549 and about 1543 ng·h/mL;

after administration of a single dose of 120 mg of the active agent a mean norketamine AUC 0-∞ of about 2133 ng·h/mL or a norketamine AUC 0-∞ between about 1353 and about 3260 ng·h/mL;

after administration of a single dose of 240 mg of the active agent a mean norketamine AUC 0-∞ of about 4087 ng·h/mL or a norketamine AUC 0-∞ between about 3205 and about 5216 ng·h/mL;

after administration of 5 doses of 60 mg ketamine administered every 12 hours a mean ketamine Cmax of about 12 ng/ml or a ketamine Cmax between about 8 and about 23 ng/ml;

after administration of 5 doses of 120 mg ketamine administered every 12 hours a mean ketamine Cmax of about 21 ng/ml or a ketamine Cmax between about 7 and about 45 ng/ml;

after administration of 5 doses of 240 mg ketamine administered every 12 hours a mean ketamine Cmax of about 42 ng/ml or a ketamine Cmax between about 33 and about 53 ng/ml;

after administration of 5 doses of 60 mg of the active agent administered every 12 hours a mean norketamine Cmax of about 125 ng/ml or a norketamine Cmax between about 85 and about 185 ng/ml;

after administration of 5 doses of 120 mg of the active agent administered every 12 hours a mean norketamine Cmax of about 230 ng/mL or a norketamine Cmax between about 168 and about 335 ng/ml;

after administration of 5 doses of 240 mg of the active agent administered every 12 hours a mean norketamine Cmax of about 421 ng/ml or a norketamine Cmax between about 363 and about 474 ng/ml;

after administration of 5 doses of 60 mg ketamine administered every 12 hours a mean ketamine AUC 0-12 of about 74 ng·h/mL or a ketamine AUC 0-12 between about 35 and about 156 ng·h/mL;

after administration of 5 doses of 120 mg ketamine administered every 12 hours a mean ketamine AUC 0-12 of about 133 ng·h/mL or a ketamine AUC 0-12 between about 58 and about 287 ng·h/mL;

after administration of 5 doses of 240 mg ketamine administered every 12 hours a mean ketamine AUC 0-12 of about 221 ng·h/mL or a ketamine AUC 0-12 between about 145 and about 328 ng·h/mL;

after administration of 5 doses of 60 mg of the active agent administered every 12 hours a mean norketamine AUC 0-12 of about 981 ng·h/mL or a norketamine AUC 0-12 between about 608 and about 1583 ng·h/mL;

after administration of 5 doses of 120 mg of the active agent administered every 12 hours a mean norketamine AUC 0-12 of about 1697 ng·h/mL or a norketamine AUC 0-12 between about 1124 and about 2557 ng·h/mL;

after administration of 5 doses of 240 mg of the active agent administered every 12 hours a mean norketamine AUC 0-12 of about 3025 ng·h/mL or a norketamine AUC 0-12 between about 2381 and about 3666 ng·h/mL;

a mean tmax of said active agent between about 1.5 and about 3.5 hours after administration of a single dose of 60 mg or 120 mg or 240 mg;

a mean tmax of said active agent between about 1.5 and about 3.5 hours after administration of 5 doses of 60 mg administered every 12 hours;

a mean tmax of said active agent between about 1.5 and about 3.5 hours after administration of 5 doses of 120 mg administered every 12 hours; and

a mean tmax of said active agent between about 1.5 and about 3.5 hours after administration of 5 doses of 240 mg administered every 12 hours;

a ratio of norketamine Cmax:ketamine Cmax of between about 4 to about 15 when said tablet is administered at a single dose of about 60 mg to a patient; and

a ratio of norketamine AUC:ketamine AUC of between about 7 to about 15 when said tablet is administered at a single dose of about 60 mg to a patient.

2 . The tablet of claim 1 wherein the tablet comprises about 30 mg, about 60 mg, about 120 mg, about 180 mg, or about 240 mg of the active agent.

3 . The tablet of claim 1 wherein the tablet is suitable for once daily administration or twice-daily administration to a patient.

4 . The tablet of claim 1 wherein the tablet has no or minimal dissociative side effects upon administration to a patient.

5 . A method of treating a patient for a condition selected from the group consisting of treatment-resistant depression; and treatment-resistant anxiety, including but not limited to DSM-V Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and/or Obsessive-Compulsive Disorder, comprising:

i. selecting a patient in need of treatment for a condition selected from the group consisting of treatment-resistant depression; and treatment-resistant anxiety, including but not limited to DSM-V Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and/or Obsessive-Compulsive Disorder; and

ii. orally administering to the patient the tablet of claim 1 ,

wherein the tablet treats the symptoms of said condition selected from the group consisting of treatment-resistant depression; and treatment-resistant anxiety, including but not limited to DSM-V Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and/or Obsessive-Compulsive Disorder.

6 . The method of claim 5 wherein the tablet comprises about 30 mg, about 60 mg, about 120 mg, about 180 mg, or about 240 mg of the active agent.

7 . The method of claim 5 wherein the tablet is suitable for once daily administration or twice-daily administration to a patient.

8 . The method of claim 5 wherein said method comprises oral administration of a single dose of said tablet.

9 . The method of claim 5 wherein said method comprises oral administration of multiple doses of said tablet.

10 . The method of claim 5 wherein tablet has no or minimal dissociative side effects in the patient.

11 . The method of claim 5 wherein maximal mean improvements in ratings of depressed mood or anxious mood were noted after approximately 6 weeks of maintenance treatment.

12 . The method of claim 5 further comprising administering a pharmaceutically effective dose of a second or additional therapy, wherein said second or additional therapy has antidepressant properties.

13 . The method of claim 5 wherein said method further comprises an additional therapy selected from:

at least one antidepressant selected from the group consisting of citalopram, escitalopram oxalate, fluoxetine, fluvoxamine, paroxetine, sertraline, dapoxetine; venlafaxine and duloxetine; harmaline, iproniazid, isocarboxazid, nialamide, pargyline, phenelzine, selegiline, toloxatone, tranylcypromine, brofaromine, moclobemide; amitriptyline, amoxapine, butriptyline, clomipramine, desipramine, dibenzepin, dothiepin, doxepin, imipramine, iprindole, lofepramine, melitracen, nortriptyline, opipramol, protriptyline, trimipramine; maprotiline, mianserin, nefazodone, trazodone, pharmaceutically acceptable salts, isomers, and combinations thereof;

at least one mood stabilizer selected from the group consisting of lithium carbonate, lithium orotate, lithium salt, valproic acid, divalproex sodium, sodium valproate, lamotrigine, carbamazepine, gabapentin, oxcarbazepine, topiramate, pharmaceutically acceptable salts, isomers, and combinations thereof;

at least one herbal antidepressant selected from the group consisting of St. John's Wort; Kava kava; echinacea ; saw palmetto; holy basil; valerian; milk thistle; Siberian ginseng ; Korean ginseng; ashwagandha root; nettle; Ginkgo biloba ; gotu kola; ginkgo /gotu kola supreme; astragalus ; goldenseal; dong quai; ginseng ; St. John's wort supreme; echinacea ; bilberry, green tea; hawthorne; ginger, gingko , turmeric; Boswellia serata ; black cohosh; cats claw; catnip; chamomile; dandelion; chaste tree berry; black elderberry; feverfew; garlic; horse chestnut; licorice; red clover blossom and leaf Rhodiola rusa; Coleus forskohlii ; Passion Flower; eyebright; yohimbe; blueberry plant; black pepper plant; Hydrocotyle asiatica; astragalus ; valerian poppy root and grape seed; vervain; Echinacea ang root; Skull Cap; serenity elixir; and combinations thereof;

at least one antipsychotic agent selected from the group consisting of haloperidol, chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, levomepromazine, promethazine, chlorprothixene, flupenthixol, thiothixene, zuclopenthixol, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, paliperidone, dopamine, bifeprunox, norclozapine, aripiprazole, tetrabenazine, cannabidiol, pharmaceutically acceptable salts, isomers, and combinations thereof;

other therapeutic interventions selected from the group consisting of counseling, psychotherapy, cognitive therapy, electroconvulsive therapy, hydrotherapy, hyperbaric oxygen therapy, electrotherapy and electrical stimulation, transcutaneous electrical nerve stimulation (“TENS”), deep brain stimulation, vagus nerve stimulation, and transcranial magnetic stimulation, and

combinations thereof.

14 . A method of treating a patient for a condition selected from the group consisting of treatment-resistant depression; and treatment-resistant anxiety, including but not limited to DSM-V Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and/or Obsessive-Compulsive Disorder, comprising:

i) selecting a patient in need of treatment of a condition selected from the group consisting of treatment-resistant depression; and treatment-resistant anxiety, including but not limited to DSM-V Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and/or Obsessive-Compulsive Disorder; and

ii) orally administering to the patient a solid, oral, extended release pharmaceutical tablet comprising a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof,

wherein said tablet comprises greater than about 25 mg of the active agent and is administered to the patient in a dosage amount of active agent selected from the group consisting of about 30 mg, about 60 mg, about 120 mg, and about 240 mg, and wherein when said tablet is administered to the patient said tablet provides a pharmacokinetic parameter selected from the group consisting of:

after administration of a single dose of 60 mg ketamine a mean ketamine Cmax of about 10 ng/mL or a ketamine Cmax between about 5 and about 15 ng/ml;

after administration of a single dose of 120 mg ketamine a mean ketamine Cmax of about 16 ng/mL or a ketamine Cmax between about 7 and about 32 ng/ml;

after administration of a single dose of 240 mg ketamine a mean ketamine Cmax of about 38 ng/ml or a ketamine Cmax between about 19 and about 47 ng/ml;

after administration of a single dose of 60 mg of the active agent a mean norketamine Cmax of about 74 ng/ml or a norketamine Cmax between about 59 and about 91 ng/ml;

after administration of a single dose of 120 mg of the active agent a mean norketamine Cmax of about 161 ng/ml or a norketamine Cmax between about 90 and about 250 ng/ml;

after administration of a single dose of 240 mg of the active agent a mean norketamine Cmax of about 315 ng/ml or a norketamine Cmax between about 222 and about 394 ng/ml;

after administration of a single dose of 60 mg ketamine a mean ketamine AUC 0-∞ of about 79 ng·h/mL or a ketamine AUC 0-∞ between about 36 and about 135 ng·h/mL;

after administration of a single dose of 120 mg ketamine a mean ketamine AUC 0-∞ of about 197 ng·h/mL or a ketamine AUC 0-∞ between about 93 and about 460 ng·h/mL;

after administration of a single dose of 240 mg ketamine a mean ketamine AUC 0-∞ of about 389 ng·h/mL or a ketamine AUC 0-∞ between about 231 and about 521 ng·h/mL;

after administration of a single dose of 60 mg of the active agent a mean norketamine AUC 0-∞ of about 872 ng·h/mL or a norketamine AUC 0-∞ between about 549 and about 1543 ng·h/mL;

after administration of a single dose of 120 mg of the active agent a mean norketamine AUC 0-∞ of about 2133 ng·h/mL or a norketamine AUC 0-∞ between about 1353 and about 3260 ng·h/mL;

after administration of a single dose of 240 mg of the active agent a mean norketamine AUC 0-∞ of about 4087 ng·h/mL or a norketamine AUC 0-∞ between about 3205 and about 5216 ng·h/mL;

after administration of 5 doses of 60 mg ketamine administered every 12 hours a mean ketamine Cmax of about 12 ng/ml or a ketamine Cmax between about 8 and about 23 ng/mL;

after administration of 5 doses of 120 mg ketamine administered every 12 hours a mean ketamine Cmax of about 21 ng/ml or a ketamine Cmax between about 7 and about 45 ng/ml;

after administration of 5 doses of 240 mg ketamine administered every 12 hours a mean ketamine Cmax of about 42 ng/ml or a ketamine Cmax between about 33 and about 53 ng/mL;

after administration of 5 doses of 60 mg of the active agent administered every 12 hours a mean norketamine Cmax of about 125 ng/mL or a norketamine Cmax between about 85 and about 185 ng/ml;

after administration of 5 doses of 120 mg of the active agent administered every 12 hours a mean norketamine Cmax of about 230 ng/ml or a norketamine Cmax between about 168 and about 335 ng/ml;

after administration of 5 doses of 240 mg of the active agent administered every 12 hours a mean norketamine Cmax of about 421 ng/ml or a norketamine Cmax between about 363 and about 474 ng/ml;

after administration of 5 doses of 60 mg ketamine administered every 12 hours a mean ketamine AUC 0-12 of about 74 ng·h/mL or a ketamine AUC 0-12 between about 35 and about 156 ng·h/mL;

after administration of 5 doses of 120 mg ketamine administered every 12 hours a mean ketamine AUC 0-12 of about 133 ng·h/mL or a ketamine AUC 0-12 between about 58 and about 287 ng·h/mL;

after administration of 5 doses of 240 mg ketamine administered every 12 hours a mean ketamine AUC 0-12 of about 221 ng·h/mL or a ketamine AUC 0-12 between about 145 and about 328 ng·h/mL;

after administration of 5 doses of 60 mg of the active agent administered every 12 hours a mean norketamine AUC 0-12 of about 981 ng·h/mL or a norketamine AUC 0-12 between about 608 and about 1583 ng·h/mL;

after administration of 5 doses of 120 mg of the active agent administered every 12 hours a mean norketamine AUC 0-12 of about 1697 ng·h/mL or a norketamine AUC 0-12 between about 1124 and about 2557 ng·h/mL;

after administration of 5 doses of 240 mg of the active agent administered every 12 hours a mean norketamine AUC 0-12 of about 3025 ng·h/mL or a norketamine AUC 0-12 between about 2381 and about 3666 ng·h/mL;

a mean tmax of said active agent between about 1.5 and about 3.5 hours after administration of a single dose of 60 mg or 120 mg or 240 mg;

a mean tmax of said active agent between about 1.5 and about 3.5 hours after administration of 5 doses of 60 mg administered every 12 hours;

a mean tmax of said active agent between about 1.5 and about 3.5 hours after administration of 5 doses of 120 mg administered every 12 hours;

a mean tmax of said active agent between about 1.5 and about 3.5 hours after administration of 5 doses of 240 mg administered every 12 hours;

a ratio of norketamine Cmax:ketamine Cmax of between about 4 to about 15 when said tablet is administered at a single dose of about 60 mg to a patient; and

a ratio of norketamine AUC:ketamine AUC of between about 7 to about 15 when said tablet is administered at a single dose of about 60 mg to a patient,

wherein the tablet treats the symptoms of said condition selected from the group consisting of treatment-resistant depression; and treatment-resistant anxiety, including but not limited to DSM-V Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and/or Obsessive-Compulsive Disorder.

15 . The method of claim 14 wherein the tablet comprises about 30 mg, about 60 mg, about 120 mg, about 180 mg, or about 240 mg of the active agent.

16 . The method of claim 14 wherein the tablet is suitable for once daily administration or twice-daily administration to a patient.

17 . The method of claim 14 wherein said method comprises oral administration of a single dose of said tablet.

18 . The method of claim 14 wherein said method comprises oral administration of multiple doses of said tablet.

19 . The method of claim 14 wherein tablet has no or minimal dissociative side effects in the patient.

20 . The method of claim 14 wherein maximal mean improvements in ratings of depressed mood or anxious mood were noted after approximately 6 weeks of maintenance treatment.

21 . The method of claim 14 further comprising administering a pharmaceutically effective dose of a second or additional therapy, wherein said second or additional therapy has antidepressant properties.

22 . The method of claim 14 wherein said method further comprises an additional therapy selected from:

at least one antidepressant selected from the group consisting of citalopram, escitalopram oxalate, fluoxetine, fluvoxamine, paroxetine, sertraline, dapoxetine; venlafaxine and duloxetine; harmaline, iproniazid, isocarboxazid, nialamide, pargyline, phenelzine, selegiline, toloxatone, tranylcypromine, brofaromine, moclobemide; amitriptyline, amoxapine, butriptyline, clomipramine, desipramine, dibenzepin, dothiepin, doxepin, imipramine, iprindole, lofepramine, melitracen, nortriptyline, opipramol, protriptyline, trimipramine; maprotiline, mianserin, nefazodone, trazodone, pharmaceutically acceptable salts, isomers, and combinations thereof;

at least one mood stabilizer selected from the group consisting of lithium carbonate, lithium orotate, lithium salt, valproic acid, divalproex sodium, sodium valproate, lamotrigine, carbamazepine, gabapentin, oxcarbazepine, topiramate, pharmaceutically acceptable salts, isomers, and combinations thereof;

at least one herbal antidepressant selected from the group consisting of St. John's Wort; Kava kava; echinacea ; saw palmetto; holy basil; valerian; milk thistle; Siberian ginseng ; Korean ginseng; ashwagandha root; nettle; Ginkgo biloba ; gotu kola; ginkgo /gotu kola supreme; astragalus ; goldenseal; dong quai; ginseng ; St. John's wort supreme; echinacea ; bilberry, green tea; hawthorne; ginger, gingko , turmeric; Boswellia serata ; black cohosh; cats claw; catnip; chamomile; dandelion; chaste tree berry; black elderberry; feverfew; garlic; horse chestnut; licorice; red clover blossom and leaf Rhodiola rusa; Coleus forskohlii ; Passion Flower; eyebright; yohimbe; blueberry plant; black pepper plant; Hydrocotyle asiatica; astragalus ; valerian poppy root and grape seed; vervain; Echinacea ang root; Skull Cap; serenity elixir; and combinations thereof;

at least one antipsychotic agent selected from the group consisting of haloperidol, chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, levomepromazine, promethazine, chlorprothixene, flupenthixol, thiothixene, zuclopenthixol, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, paliperidone, dopamine, bifeprunox, norclozapine, aripiprazole, tetrabenazine, cannabidiol, pharmaceutically acceptable salts, isomers, and combinations thereof;

other therapeutic interventions selected from the group consisting of counseling, psychotherapy, cognitive therapy, electroconvulsive therapy, hydrotherapy, hyperbaric oxygen therapy, electrotherapy and electrical stimulation, transcutaneous electrical nerve stimulation (“TENS”), deep brain stimulation, vagus nerve stimulation, and transcranial magnetic stimulation, and

combinations thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2024
From: SURMAN, PETER WILLIAM
To: DOUGLAS PHARMACEUTICALS LTD
Reel/Frame 067286/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2022
From: GLUE, PAUL WILLIAM; MEDLICOTT, NATALIE JUNE
To: UNIVERSITY OF OTAGO
Reel/Frame 061043/0886 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2022
From: UNIVERSITY OF OTAGO
To: OTAGO INNOVATION LIMITED
Reel/Frame 061044/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2022
From: OTAGO INNOVATION LIMITED
To: DOUGLAS PHARMACEUTICALS LTD.
Reel/Frame 061044/0066 →
Continuity (4)
Continuation 17442239
Continuation 16362848 · Mar 25, 2019
Continuation In Part 15728695 · Oct 10, 2017
Related Publication 20220387355A1 · Dec 8, 2022
References Cited (262)
US 3723614A · Langauer · 1973 [cited by applicant]
US 6194000B1 · Smith · 2001 [cited by applicant]
US 6280770B1 · Pather et al. · 2001 [cited by applicant]
US 6692771B2 · Pather et al. · 2004 [cited by applicant]
US 6855735B2 · Friedman · 2005 [cited by applicant]
US 7776314B2 · Bartholomaus et al. · 2010 [cited by applicant]
US 8114383B2 · Bartholomaus et al. · 2012 [cited by applicant]
US 8137711B2 · Wolicki · 2012 [cited by applicant]
US 8309060B2 · Bartholomaus et al. · 2012 [cited by applicant]
US 9272037B2 · Singh · 2016 [cited by applicant]
US 9533982B2 · Conn et al. · 2017 [cited by applicant]
US 9650362B2 · Wainer et al. · 2017 [cited by applicant]
US 9867830B2 · Wainer et al. · 2018 [cited by applicant]
US 10335379B2 · Manthei et al. · 2019 [cited by applicant]
US 10441544B2 · Glue et al. · 2019 [cited by applicant]
US 10744094B2 · Glue et al. · 2020 [cited by applicant]
US 10869838B2 · Glue et al. · 2020 [cited by applicant]
US 11045424B2 · Glue et al. · 2021 [cited by applicant]
US 11103467B2 · Manthei et al. · 2021 [cited by applicant]
US 11471415B2 · Glue et al. · 2022 [cited by applicant]
US 11471416B2 · Glue · 2022 [cited by examiner]
US 12090123B2 · Glue · 2024 [cited by examiner]
US 12128140B2 · Glue · 2024 [cited by examiner]
US 20050038062A1 · Burns et al. · 2005 [cited by applicant]
US 20080268071A1 · Gant et al. · 2008 [cited by applicant]
US 20090004281A1 · Nghiem et al. · 2009 [cited by applicant]
US 20090131794A1 · Yao et al. · 2009 [cited by applicant]
US 20090202634A1 · Jans et al. · 2009 [cited by applicant]
US 20090253728A1 · Meyerson et al. · 2009 [cited by applicant]
US 20100029665A1 · Meyerson et al. · 2010 [cited by applicant]
US 20130217615A1 · Lasser et al. · 2013 [cited by applicant]
US 20130281388A1 · Deaver et al. · 2013 [cited by applicant]
US 20140050787A1 · Tygesen et al. · 2014 [cited by applicant]
US 20140079740A1 · Salama · 2014 [cited by applicant]
US 20140112984A1 · Arkenau-Maric et al. · 2014 [cited by applicant]
US 20150057306A1 · Fava et al. · 2015 [cited by applicant]
US 20150342947A1 · Pollard et al. · 2015 [cited by applicant]
US 20160101069A1 · Charney et al. · 2016 [cited by applicant]
US 20160106808A1 · Charney et al. · 2016 [cited by applicant]
US 20160199304A1 · Nivorozhkin et al. · 2016 [cited by applicant]
US 20170020820A1 · Sackler · 2017 [cited by applicant]
US 20170035707A1 · Manthei et al. · 2017 [cited by applicant]
US 20170042878A1 · Fava et al. · 2017 [cited by applicant]
US 20170355663A1 · Nivorozhkin et al. · 2017 [cited by applicant]
US 20180098993A1 · Wainer et al. · 2018 [cited by applicant]
US 20180153813A1 · Nivorozhkin et al. · 2018 [cited by applicant]
US 20190105276A1 · Glue et al. · 2019 [cited by applicant]
US 20190216740A1 · Glue et al. · 2019 [cited by applicant]
US 20200000731A1 · Glue · 2020 [cited by applicant]
US 20200323795A1 · Glue et al. · 2020 [cited by applicant]
US 20210052517A1 · Glue et al. · 2021 [cited by applicant]
US 20220183983A1 · Glue et al. · 2022 [cited by applicant]
US 20220347104A1 · Glue · 2022 [cited by examiner]
US 20220354798A1 · Glue · 2022 [cited by examiner]
US 20220387355A1 · Glue et al. · 2022 [cited by applicant]
US 20240189259A2 · Glue · 2024 [cited by examiner]
US 20250049734A1 · Glue · 2025 [cited by examiner]
DE 102007009888 · 2008 [cited by applicant]
EP 1103256 · 2001 [cited by applicant]
WO 2009131794 · 2009 [cited by applicant]
WO 2013008135 · 2013 [cited by applicant]
WO 2013149102 · 2013 [cited by applicant]
WO 2014020155 · 2014 [cited by applicant]
WO 2014169272 · 2014 [cited by applicant]
WO 2015031410 · 2015 [cited by applicant]
WO 2016073653 · 2016 [cited by applicant]
WO 2018234568 · 2018 [cited by applicant]
WO WO2019073408 · 2019 [cited by applicant]
Adhvaryu et al. (1986) “Genetoxic effects of ketamine on CHO cells” Arch Toxicology 59:124-125. [cited by applicant]
Amorsa Therapeutics Inc (2014) “Developing a novel treatment for refractory cancer pain” Cancer Cluster Showcase BIO 2014 website www.amorsatx.com. [cited by applicant]
Anderson et al. (2008) “Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychpharmacology guidelines” A Journal of Psychopharmacology 22(4… [cited by applicant]
Amin et al. (2014) “Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain” J Pain Palliat Care Pharmacother 28(3): 233-242. [cited by applicant]
Baker et al. (2016) “Ketamine-induced apoptosis in normal human urothelial cells: a direct, N-methyl-d-aspartate receptor-independent pathway characterized by mitochondrial stress” Am J Pathol 186(5): 1267-1277. [cited by applicant]
Barkan et al. (2014)“A double blind, randomised, placebo controlled trial of oral midazolam plus oral ketamine for sedation of children during laceration repair” Emergency Medicine Journal 31(8) 649-653. [cited by applicant]
Bartova (2017) “Robust antidepressant effect following alternating intravenous racemic ketamine and electroconvulsive therapy in treatment-resistant depression: a case report” Journal of ECT 00(00). [cited by applicant]
Berman et al. (2000) “Antidepressant effects of ketamine in depressed patients” Biol Psychiatry 47:351-354. [cited by applicant]
Beaudoin et al. (2014) “Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial” Acad Emerg Med … [cited by applicant]
Boulieu (1998) “HPLC determination of ketamine, norketamine, and dehydronorketamine in plasma with a high-purity reversed-phase sorbent” Clinical Chemistry 44(3): 560-564. [cited by applicant]
Bredlau et al. (2013) “Oral ketamine for children with chronic pain: a pilot phase 1 study” J Pediatr 163(1): 194-200 e191. [cited by applicant]
Bremner et al. (1998) “Measurement of dissociative states with the clinical-administered dissociative states scale (CADSS)” Journal of Traumatic Stress 11(1). [cited by applicant]
Brooks (2016) “Repeated ketamine may sustain antidepressant effect” American Journal of Psychiatry. [cited by applicant]
Brown et al. (1996) “Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders” American Journal of Psychiatry 153(10):1293-1300. [cited by applicant]
Brunette et al. (2011) “Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures” Pediatric Anesthetics 21(6):653-662. [cited by applicant]
Busner (2007) “The clinical global impressions scale: applying a research tool in clinical practice” Psychiatry 4:28-37. [cited by applicant]
Caddy et al. (2014) “Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions and a systematic review and meta-analysis of efficacy” Therapeutic Advances in Psychopharmacology 4(2):75-99. [cited by applicant]
Cani et al. (2015) “Endocannabinoids—at the crossroads between the gut microbiota and host metabolism” Nature Reviews Endocrinology 12(3): 133-143. [cited by applicant]
Carliss et al. (2007) “Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain” Science Direct Neuro Toxicology 28: 813-818. [cited by applicant]
Carreno et al. (2016) “Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine” Mol Psychiatry 21(9):1298-1308. [cited by applicant]
Chang et al. (2004) “Mechanisms involved in the antiplatelet activity of ketamine in human platelets” Journal of Biomed Science 11:764-772. [cited by applicant]
Chen et al. (1998) “Neuroprotective concentrations of the N-methyl D-aspartate open channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze le… [cited by applicant]
Chen et al. (2012) “Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression” Expert Opinion Drug Metabolism Toxicology 6(3):273-281. [cited by applicant]
Chong et al. (2009) “Development of sublingual/oral formulation of ketamine for use in neuropathic pain” Clinical Drug Investigation 29(5):317-324. [cited by applicant]
Clements, Grant (1981) “Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans” Journal of Pharmaceutical Sciences 71(5):539-542. [cited by applicant]
Conway et al. (2017) “Toward an evidence-based, operational definition of treatment-resistant depression, when enough is enough” JAMA Psychiatry 74(1): 9-10. [cited by applicant]
Correll et al. (2006) “Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions” Pain Medicine 7(1):92-95. [cited by applicant]
Coyle et al. (2013) “Nitric oxide and symptom reduction in Schizophrenia” Jama Psychiatry 70(7):664-665. [cited by applicant]
Cox (2019) “Ketamine: Can it really be an antidepressant?” The Guardian, https://theguardian.com/science2019/mar23/ketamine-can-it-really-be-an-antidepressant (pp. 1-7). [cited by applicant]
Critical review of ketamine 34th ECDD 2006/4.3, Sep. 2002. [cited by applicant]
Cvrcek (2008) “Side effects of ketamine in the long-term treatment of neuropathic pain” Pain Medicine 9(2):253-257. [cited by applicant]
Daly et al. (2018) “Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial” JAMA psychiatry 75(2):139-148. [cited by applicant]
Daly et al. (2019) “Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial” JAMA Psychiatry 76:893-903. [cited by applicant]
Declaration of Paul William Glue under 37 C.F.R. 1.132 submitted in parent U.S. Appl. No. 16/362,848 dated Jul. 6, 2020. [cited by applicant]
Declaration of Zhen shi under 37 C.F.R. 1.132 submitted in parent U.S. Appl. No. 16/362,848 dated Jul. 6, 2020. [cited by applicant]
De Gioannis et al. (2014) “Oral ketamine augmentation for chronic suicididality in treatment-resistant depression” Aust N Z J Psychiatry 48(7): 686. [cited by applicant]
Domino et al. (1982) “Plasma levels of ketamine and two of its metabolities in surgical patients using a gas chromatographic mass fragmentographic assay” Anesthesia and Analgesia 61:87-92. [cited by applicant]
Downey et al. (2016) “Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate” European Neuropsychopharmacology 26(6):994-1003. [cited by applicant]
Duman et al. (2012) “Signaling pathways underlying the rapid antidepressant actions of ketamine” Neuropharmacology 62(1):35-41. [cited by applicant]
Ebert et al. (1997) “Norketamine: the main metabolite of ketamine is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord” European Journal of Pharmacology 20(333)(1):99-104. [cited by applicant]
Emarson (1999) “Clinical experience with oral ketamine” Journal of Pain and Symptom Management 17(5). [cited by applicant]
Erdil et al. (2015) “Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy” J Anesth 29(2): 180-185. [cited by applicant]
Fanta et al. (2015) “Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing” Eur J Clin Pharmacol 71(4):441-7. [cited by applicant]
Feder (2014) “Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder” JAMA Psychiatry 71(6):681-688. [cited by applicant]
Fekadu et al. (2009) “A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method” Journal of Clinical Psychiatry 70(2):177-184. [cited by applicant]
Fields et al. (2015) “Pill properties that cause dysphagia and treatment failure” Current Therapeutic Research 77: 79-82. [cited by applicant]
Fox et al. (2012) “Developmental origins of adult diseases and neurotoxicity: epidemiological and experimental studies” Neurotoxicology 33(4):810-816. [cited by applicant]
Fredriksson et al. (2004) “Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD” Neurotoxicity Research 6(6):435-456. [cited by applicant]
Furuhashi-Yonaha (2002) “Short and long-term efficacy of oral ketamine in eight chronic pain patients” Canadian Journal of Anesthesia 886-887. [cited by applicant]
Ghasemi et al. (2014) “Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder” Psychiatry Res 215(2): 355-361. [cited by applicant]
Gills (1995) “Normative values for the beck anxiety inventory, fear questionnaire, Penn State worry questionnaire, and social phobia and anxiety inventory” Psychological Assessment 7(4):450-455. [cited by applicant]
Glue et al. (2010) “Meta-analysis of relapse prevention antidepressant trials in depressive disorders” Aust NZ J Psychiatry 44:697-705. [cited by applicant]
Glue et al. (2017) “Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders” Journal of Psychopharmacology 31(10):1302-1305. [cited by applicant]
Glue et al. (2018) “Safety and efficacy of maintenance ketamine treatments in patients with treatment-refractory generalised anxiety and social anxiety disorders” Journal of Psychopharmacology 32(6) https://doi.org/10.1… [cited by applicant]
Glue et al. (2021) “Influence of formulation and route of administration on ketamine's safety and tolerability: systematic review” Eur J Clin Pharmacol 77:671-676. [cited by applicant]
Gough et al. (1995) “Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party” Drug Information Journal 29:1039-1048. [cited by applicant]
Grande et al. (2016) “(417) Oral ketamine for chronic pain: a 32-subject placebo-controlled trial in patients on chronic opioids” The Journal of Pain 17(4): S78-S79. [cited by applicant]
Grant (1981) “Pharmacokinetics and analgesic effects of I.M. and oral ketamine” British Journal of Anesthesia 53(8):805-810. [cited by applicant]
Haile et al. (2014) “Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression” International Journal of Neuropsychopharmacology 17(2):331-336. [cited by applicant]
Hallak et al. (2013) “Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial” JAMA Psychiatry 70(7):668-676. [cited by applicant]
Hamilton (1957) “The assessment of anxiety states by rating” Department of Psychiatry, University of Leeds p. 50-55. [cited by applicant]
Harraz et al. (2016) “Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation” Molecular Psychiatry 21(3):313-9. [cited by applicant]
Hartberg et al. (2018) “Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study” Psychopharmacology (Berl) 235(2):393-398. [cited by applicant]
Hasan et al. (2021) “Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects” Anesthesiology 135:326-339. [cited by applicant]
Hocking, Cousins (2003) “Ketamine in chronic pain management: an evidence-based review” Anesthesia and Analgesia 97(6): 1730-1739. [cited by applicant]
Horacek (2012) “The influence of clonidine on oral ketaminemidazolam premedication in intellectually disabled patients indicated for . . . ” Neuro Endocrinology Letters 33(4):380-384. [cited by applicant]
Hu et al. (2016) “Single IV ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study” Psychol Med 46(3): 623-635. [cited by applicant]
Huang et al. (2016) “Ketamine affects the neurogenesis of the hippocampal dentate gyrus in 7 day old rats” Neurotox Rex 30:185-198. [cited by applicant]
Humphrey et al. (2012) “The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score” European Association of Urology 61:271-279. [cited by applicant]
International Search Report dated Dec. 27, 2021 for PCT/IB2021/058647. [cited by applicant]
International Search Report dated Jan. 28, 2019 for PCT/IB2018/057851. [cited by applicant]
Ionescu et al. (2014) “Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine” J Clin Psychiatry 75(9): e932-938. [cited by applicant]
Irwin et al. (2010) “Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care” Journal of Palliative Medicine 13(7):903-908. [cited by applicant]
Irwin (2013) “Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial” Journal of Palliative Medicine 16(8):958-965. [cited by applicant]
Jafarina et al. (2016) “efficacy and safety or oral ketamine versus diclofanec to alleviate mild to moderate depression in chronic pain patients: a double blind, randomized, controlled trial” J affect discord 204:1-8. [cited by applicant]
Janssen (2000), “Ketamine dreams and realities” Florida, USA, Multidisciplinary Association for Psychedelic Studies (MAPS). [cited by applicant]
Janssen (2015) “A study of evaluate the efficacy, safety, and tolerability of intranasal eskatimine plus an oral antidepressant in elderly participants with treatment-resistant depression” Transform 3. [cited by applicant]
Janssen (2015) “Ketamine plus lithium in treatment-resistant depression” Study. [cited by applicant]
Janssen (2015) “Ketamine trial for the treatment of depression”. [cited by applicant]
Janssen Research and Development (2014) “A double-blind, doubly-randomized, placebo-controlled study of intranasal esketamine in an adaptive treatment protocol to assess safety and efficacy in treatment-resistant depres… [cited by applicant]
Janssen Research and Development (2015) “A study of ketamine in patients with treatment-resistant depression”. [cited by applicant]
Janssen Research and Development (2015) “A study to evaluate the efficacy, safety, and tolerability of flexible doses of intranasal esketamine plus an oral antidepressant in adult participants with treatment-resistant d… [cited by applicant]
Jarventausta et al. (2013) “Effects of s-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study” J ECT 29(3): 158-16… [cited by applicant]
Jennings et al. (2013) “Oral ketamine for sickle cell crisis pain refractory to opioids” J Pain Palliat Care Pharmacotherapy 27(2): 150-154. [cited by applicant]
Jevtovice-Todorovic (2001) “A comparative evaluation of neurotoxic properties of ketamine and nitrous oxide” Brain Research 895:264-267. [cited by applicant]
Kannan, Bhatnagar (2002) “Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients” Journal of Pain and Symptom Management 23(1):60-65. [cited by applicant]
Katalinic et al. (2013) “Ketamine as a new treatment for depression: a review of its efficacy and adverse effects” Australian & New Zealand Journal of Psychiatry 47(8): 710-727. [cited by applicant]
Kessler et al. (2011) The global burden of mental disorders: an update from the WHO world mental health (WMH) surveys Epidemiology and Psychiatric Sciences 18(1):23-33. [cited by applicant]
Koksal (2015) “Analysis of genotoxic activity of ketamine and rocuronium bromide using the somatic mutation and recombination test in [cited by applicant]
Kritzer et al. (2022) “Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability” Expert Opinion Drug Safety 21:727-732. [cited by applicant]
Kundra et al. (2013) “Oral ketamine and dexmedetomidine in adults' burns wound dressing—a randomized double blind cross over study” Burns 39(6):1150-1156. [cited by applicant]
Lai et al. (2014) “Pilot dose-response trial of IV ketamine in treatment-resistant depression” World J Biol Psychiatry 15(7): 579-584. [cited by applicant]
Lara et al. (2013) “Antidepressant, mood stabilizing and precognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression” International Journal of Neuropsychopharmacology 16(9): 2… [cited by applicant]
Leffa et al. (2016) Anesthetic ketamine-induced DNA damage in different cell types in vivo Mol Neurobiol 53(8): 5575-581. [cited by applicant]
Lenze et al. (2016): “Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: a pilot randomised controlled trial” World J Biol Psychiatry 17(3):230-238. [cited by applicant]
Li et al. (2010) “mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists” Science 329(5994):959-964. [cited by applicant]
Li et al. (2016) “The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study” Hum Brain Mapp 37(3): 1080-1090. [cited by applicant]
Locklear (2016) “Drug quickly quells suicidal thoughts” New Scientist p. 12. [cited by applicant]
Loo et al. (2012) “Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial” J Affect Disord 142(1-3):233-240. [cited by applicant]
Loo et al. (2016) “Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular, and subcutaneous routes for ketamine in depression” Acta Psychiatry Scand 134(1):48-56, doi 10, 111/acps. 12572, E… [cited by applicant]
Lu et al. (2012) “Sedating pediatric dental patients by oral ketamine with alternating bi-lateral stimulation of eye movement desensitization and minimizing adverse reaction of ketamine by acupuncture and bi-digital o-r… [cited by applicant]
Maggi et al. (2002) “Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (POs) for the controlled release of a water-soluble drug. Dimensionality study” Biomaterials 23:1113-… [cited by applicant]
Malhi et al. (2009) “Clinical practice recommendations for depression” Acta Psychiatry Scand Supply 439:8-26. [cited by applicant]
Manji, Mullard (2015) “Husseini Manji” Nat Rev Drug Discovery 14(11): 742-743. [cited by applicant]
Marchetti et al. (2015) “Efficacy and safety of oral ketamine for the relief of intractable chronic pain: a retrospective 5-year study of 51 patients” Eur J Pain 19(7): 984-993. [cited by applicant]
Matthew et al. (2012) “Ketamine for treatment-resistant unipolar depression: current evidence” CNS Drugs 26(3): 189-204. [cited by applicant]
McClintock et al. (2014) “Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy” J ECT 30(2): 165-176. [cited by applicant]
McNulty (2012) “Compounded oral ketamine for severe depression, anxiety, pain in a hospice patient with end-stage chronic obstructive pulmonary disease, cardiopulmonary failure, and severe renal insufficiency: a case re… [cited by applicant]
Melander et al. (2008) “A regulatory Apologia—a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants” Eur Neuropsychopharmacol 18:623-627. [cited by applicant]
Meneguz et al. (1999) “Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo” Exp Toxic Pathol 51:393-396. [cited by applicant]
Moaddel et al. (2015) “D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression” Psychopharmacology (Berl) 232(2): 399-409. [cited by applicant]
Montgomery (1979) “A new depression scale designed to be sensitive to change” British Journal of Psychiatry 134:382-389. [cited by applicant]
Moreira et al. (2013) “Combined oral midazolam-ketamine better than midazolam alone for sedation of young children: a randomized controlled trial” International Journal of Pediatric Dentistry 23(3):207-215. [cited by applicant]
Motamed et al. (2012) “Midazolam-ketamine combination for moderate sedation in upper GI endoscopy” Journal of Pediatric Gastroenterology and Nutrition 54(3):422-426. [cited by applicant]
Mucalo, Rathbone (2012) “Melt-extruded polyethylene oxide (PEO) rods as drug delivery vehicles: formulation, performance as controlled release devices and the influence of co-extruded excipients on drug release profiles… [cited by applicant]
Mundt (2002) “The work and social adjustment scale: impairment in ME and depression study a simple measure of impairment in functioning” British Journal of Psychiatry 180:461-464. [cited by applicant]
Murrough et al. (2013) “Rapid and longer-term antidepressant effects of repeated Ketamine infusions in treatment-resistant major depression” Biol Psychiatry 74(4):250-256. [cited by applicant]
Murrough et al. (2015) “Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial” Psychol Med 45(16): 3571-3580. [cited by applicant]
Nemeroff (2007) “Prevalence and management of treatment-resistant depression” J Clin Psychiatry 68(8):17-25. [cited by applicant]
Newport et al. (2016) “Whither ketamine as an antidepressant: panacea or toxin” Depression and Anxiety 33(8): 685-688. [cited by applicant]
Niesters et al. (2014) “Ketamine for chronic pain: risk and benefits” Br J Clin Pharmacology 77(2): 357-367. [cited by applicant]
Noppers et al. (2011) “Effect of rifampicin on s-ketamine and s-norketamine plasma concentrations in healthy volunteers after intravenous s-ketamine administration” Anesthesiology 114(6): 1435-1445. [cited by applicant]
Norambuena et al. (2013) “Oral ketamine and midazolam for pediatric burn patients: a prospective, randomized, double-blind study” Journal of Pediatric Surgery 48(3):629-634. [cited by applicant]
Norouzi et al. (2015) “Comparison of the effects of oral vs. peritonsillar infiltration of ketamine in pain reduction after tonsillectomy: a randomized clinical trial” M.E.J. Anesth 23(1). [cited by applicant]
Novicki et al. (1985) “Inhibition of DNA synthesis by chemical carcinogens in cultures of initiated and normal proliferating rat hepatocytes” Cancer Research 45:337-344. [cited by applicant]
Nunez et al. (2020) “An update on the efficacy and tolerability of oral ketamine for major depression: A systematic review and meta-analysis”, Psychopharmacology Bulletin 50(4): 137-163. [cited by applicant]
O'Hara et al. (2014), “A 2 year experience of nurse led conscious sedation in pediatric burns” Burns 40(1): 48-53. [cited by applicant]
Olney, Price (1989) “Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs” Science 244: 1360-1362. [cited by applicant]
Olney et al. (1991) “NMDA antagonist neurotoxicity: mechanism and prevention” Science 254: 1515-1518. [cited by applicant]
Overall et al. (1984) “The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit” J Gerontol 39:187-193. [cited by applicant]
Papadimitropoulou et al. (2017) “Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis” C… [cited by applicant]
Paslaskis et al. (2010) “Oral administration of the NMDA receptor antagonist s-ketamine as add-on therapy of depression: case studies” Pharmacopsychiatry. [cited by applicant]
Paul et al. (2014) “(R-S)-ketamine metabolites (R-S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function” Anesthesiology 121: 149-159. [cited by applicant]
Peltoiemi et al. (2012) “S-ketamine concentrations are greatly increased by grapefruit juice” European Journal of Clinical Pharmacology 68(6):979-986. [cited by applicant]
Peltoiemi et al. (2012) “Rifampicin has a profound effect on the pharmacokinetics of oral s-ketamine and less on intravenous s-ketamine” Basic and Clinical Pharmacology & Toxicology 111: 325-332. [cited by applicant]
Permoda-Osip et al. (2013) “Vitamin B12 level may be related to the infusion of a single ketamine infusion in bipolar depression” Pharmacopsychiatry 46(6): 227-228. [cited by applicant]
Permoda-Osip et al. (2015) “Single ketamine infusion and neurocognitive performance in bipolar depression” Pharmacopsychiatry 48(2): 78-79. [cited by applicant]
Posner (2008) “The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults” Am J Psychiatry 168(12):1266-77. [cited by applicant]
Preskorn (2015) “Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent” J Psychiatry P… [cited by applicant]
Purdue (2009) FDA Advisory Committee on Reformulated Oxycontin FDA. [cited by applicant]
Rasmussen et al. (2013) “Serial infusions of low-dose ketamine for major depression” Journal of Psychopharmacology 27(5):444-450. [cited by applicant]
Rasmussen et al. (2014) “A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy” Psychiatry Res 215(2): 362-365. [cited by applicant]
Rao et al. (2016) “Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance” Anesthesiology 125(6): 1103-1112. [cited by applicant]
Rodriguez et al. (2013) “Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept” Neuropsychopharmacology 38(12):2475-2483. [cited by applicant]
Rofael et al. (2003) “Immunomodulation by cocaine and Ketamine in postnatal rats” Toxicology 188:101-114. [cited by applicant]
Rolan (2016) “Report on preliminary results from study KET-009”. [cited by applicant]
Rush et al. (2006) “Acute and long-term outcomes in depressed outpatients requiring one or several treatment steps: a star report” American Journal of Psychiatry 163:1905-1917. [cited by applicant]
Salvadore et al. (2013) “Ketamine as a fast acting antidepressant: current knowledge and open questions” CNS Neurosci Ther 19(6):428-436. [cited by applicant]
Sanacora et al. (2014) “Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects” Mol Psychiatry 19(9): 978-985. [cited by applicant]
Sanacora et al. (2015) “Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?” Neuropsychopharmacology 40(2):259-267. [cited by applicant]
Schoevers et al. (2016) “Oral ketamine for the treatment of pain and treatment-resistant depression” The British Journal of Psychiatry 208(2):108-113. [cited by applicant]
Segmiller et al. (2013) “Repeated S-Ketamine infusions in therapy resistant depression: a case series,” J Clin Pharmacol 53(9):996-998. [cited by applicant]
Shillinburg et al. (2017) “Treatment of severe mucositis pain with oral ketamine mouthwash” Support Care Cancer 25(7): 2215-2219. [cited by applicant]
Shirawi et al. (2017) “Oral ketamine in treatment-resistant depression: a clinical effectiveness case series” J Clin Psychopharmacol 37(4): 464-467. [cited by applicant]
Sigtermans et al. (2009) “Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1” Pain 145(3):304-311. [cited by applicant]
Short et al. (2018) “Side-effects associated with ketamine use in depression: a systematic review” Lancet Psychiatry 5:65-78. [cited by applicant]
Slikker et al. (2007) “Ketamine-induced neuronal cell death in the perinatal phesus monkey” Toxicology Sciences 98(1): 145-158. [cited by applicant]
Smeyne et al. (2016) “Assessment of the effects of MPTP and paraquat on dopaminergic neurons and microglia in the substantia nigra pars compacta of C57BL/6 mice” PLoS One 11(10): e0164094. [cited by applicant]
Smith (2000) “Confidence interval criteria for assessment of dose proportionality” Pharmaceutical Research 17(10):1278-1283. [cited by applicant]
Sos et al. (2013), “Relationship of ketamine's antidepressant and psychomimetic effects in unipolar depression” Activitas Nervosa Superior Rediviva 34(4): 287-298. [cited by applicant]
Starte et al. (2012) “Ketamine-associated corneal edema” Cornea 31(5)572-274. [cited by applicant]
Suehs et al. (2008) “ Texas Medication Algorithm Project Procedure” Manual Major Depressive Disorder Algorithms 1-68. [cited by applicant]
Swiatek et al. (2016) “New use for an old drug: oral ketamine for treatment-resistant depression” BMJ Case Rep 2016. [cited by applicant]
Teche et al. (2013) “Measurement methods of BDNF levels in major depression: a qualitative systematic review of clinical trials” Psychiatry Q 84(4): 485-497. [cited by applicant]
The Down Chemical Company (2014) Reasonable Upper Limit of the Amount of Sentry Polyox. [cited by applicant]
Viberg et al. (2008) “Neonatal ketamine exposure results in changes in biochemical substrates of neuronal growth and synaptogenisis, and alters adult behavior irreversibly” Toxicology 249: 153-159. [cited by applicant]
Wang et al. (2012) “Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder” J ECT 28(2):128-132. [cited by applicant]
Wang et al. (2013) “Preclinical assessment of ketamine” CNS Neuroscience Therapy 19(6):448-453. [cited by applicant]
Wang et al. (2013) Brain damages in ketamine addicts as revealed by magnetic resonance imaging Front Neuroanat 7:23. [cited by applicant]
Weigand (2000) “Ketamine modulates the stimulated adhesion molecule expression on human neutrophils in vitro” Anesthesia & Analgesia 90:206-212. [cited by applicant]
Wilson (2011) “Controlled release in oral drug delivery” Advances in Delivery Science and Technology 427 pages. [cited by applicant]
Wolfson (2016) “The ketamine papers” Science, Therapy, and Transformation. [cited by applicant]
Xu et al. (2016) “Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis” International Journal of Neuropsychopharmacology 19(4). [cited by applicant]
Yan (2014) “Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain” Journal of Neurosurgical Anesthesiology 26(2):155-160. [cited by applicant]
Yanagihara et al. (2003) “Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers” Biopharmaceutics & drug disposition 24(1):37-43. [cited by applicant]
Yang et al. (2015) “R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects” Translational Psychiatry 5:e632. [cited by applicant]
Yoosefi et al. (2014) “Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study” J ECT 30(1):15-21. [cited by applicant]
Yuasa et al. (1992) “Influence of anesthetic regimes on intestinal absorption in rats” Pharmaceutical Research 10(6):884-888. [cited by applicant]
Zanicotti et al. (2013) “Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer” Journal of Palliative Medicine. [cited by applicant]
Zanos et al. (2016) “NMDAR inhibition-independent antidepressant actions of ketamine metabolites” Nature 533(7604):481-486. [cited by applicant]
Zarate (2017) “Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders” Molecular Psychiatry 22(3):324-327. [cited by applicant]
Zhang et al. (2016) “Reactive oxygen species-mediated loss of phenotype of parvalbumin interneurons contributes to long term cognitive impairments after repeated neonatal ketamine exposures” Neurotox Res 30:593-605. [cited by applicant]
Zhao et al. (2012) “Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression” The British Pharmalogical Society. [cited by applicant]
Zhao et al. (2014) “Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring” Neurobiology of Disease 68:145-155. [cited by applicant]
Zhao et al. (2017) “Self-assembled ZnO nanoparticle capsules for carrying and delivering isotretinoin to cancer cells” ACS Appl Mater Interfaces 9(22):18474-18481. [cited by applicant]
Zuroff et al. (2013) “Consortia-mediated bioprocessing of cellulose to ethanol with a symbiotic Clostridium phytofermentans/yeast co-culture” Biotechnology for Biofuels 6:59. [cited by applicant]
Food and Drug Administration (FDA). FDA label Spravato. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf. Published 2019. [cited by applicant]
Glue et al. (2020) “Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study” Ther Adv Vaccines 10:1-6 doi:10.1177/2045125320922474. [cited by applicant]
Glue et al. (2020) “Ascending-dose study of controlled-release ketamine tablets in healthy volunteers: pharmacokinetics, pharmacodynamics, safety and tolerability” J Clin Pharmacol 60(6):751-757. [cited by applicant]
International Search Report from PCT/IB2020/051909 dated Sep. 8, 2020. [cited by applicant]
Kryst et al. (2020) “Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials” Pharmacol Reports (0123456789) doi:10.1007/s43440-020-00… [cited by applicant]
Peyrovian et al. (2020) “Registered clinical trials investigating ketamine for psychiatric disorders” J Psychiatr Res 127:1-12 doi:10.1016/j.jpsychires.2020.03.020. [cited by applicant]
Singh et al. (2016) “A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression” Am J Psychiatry 173(8):816-826 doi:10.1176/appi.ajp.2016… [cited by applicant]
Serafini et al. (2014) “The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review” Current Neuropharmacology 12:444-461. [cited by applicant]